Therma Bright (TSE:THRM) has released an update.
Therma Bright Inc. has announced its portfolio company InStatin’s new agreement with Mountain West Research to conduct a study aimed at enhancing the delivery of an innovative statin inhalant for asthma and COPD treatment. This research is a significant step towards the development of more effective respiratory therapies and is expected to support upcoming Phase 1 human trials. The company’s investment in InStatin aligns with the growing asthma treatment market, projected to reach USD 39.04 billion by 2032.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.